Full Year 2022 Preliminary Unaudited Total Revenues of Approximately $153-$154 Million, an 90% Increase Over Full Year 2021
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADMA:
- ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance
- ADMA Biologics price target raised to $4.50 from $4 at H.C. Wainwright
- ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®
- ADMA Biologics announces FDA approval for storage of ASCENIV, BIVIGAM
- Biotech Alert: Searches spiking for these stocks today